Savers (SVV) CPO Reports Option Exercises and Planned Sales Under 10b5-1

Rhea-AI Filing Summary

Melinda L. Geisser, Chief People Services Officer of Savers Value Village, Inc. (SVV), reported option exercises and concurrent sales executed under a 10b5-1 plan. On 08/29/2025 she recorded a 12,000-share acquisition at a $1.41 price and a matching 12,000-share sale at $11.98, leaving 0 non-derivative shares after that day's trades. On 09/02/2025 she recorded a 14,000-share acquisition at $1.41 and a concurrent 14,000-share sale at $12.48, also leaving 0 non-derivative shares after those trades. The filing states the sales were made pursuant to a 10b5-1 plan adopted March 10, 2025, and shows option grants from June 12, 2019, with vesting and performance‑based components.

Positive

• Sales were executed under a 10b5-1 plan, indicating pre-established trading arrangements and potential regulatory compliance
• Options exercised at a stated $1.41 exercise price, consistent with previously disclosed 2019 grants and vesting schedules

Negative

• Non-derivative holdings reported after the paired transactions are zero, indicating the insider did not retain the purchased shares from those specific transactions
• Significant portion of options are performance-based and remain subject to future vesting conditions, per the filing

Insights

Securities Analyst

Routine insider option exercises and plan-driven sales; no material change to long-term ownership disclosed.

The Form 4 documents exercises of previously granted options (exercise price $1.41) followed by contemporaneous market sales under a 10b5-1 plan on 08/29/2025 and 09/02/2025. The filing discloses vested time‑based and performance‑based option components from a June 12, 2019 grant and reports large numbers of underlying options remaining beneficially owned (536,373 and 522,373 following the reported derivative transactions). These transactions appear procedural and executed under a pre-established plan rather than ad hoc trading.

Corporate Governance Expert

Transactions comply with a documented 10b5-1 plan, indicating adherence to insider trading controls.

The report explicitly states the sales were made pursuant to a 10b5-1 plan adopted March 10, 2025, which provides an affirmative defense under Rule 10b5-1(c). The filing also explains the mix of time‑based and performance‑based vesting for the 2019 option grants. From a governance perspective, the presence of a documented plan and clear explanatory footnotes supports compliance and disclosure quality.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Geisser Melinda L.

(Last) (First) (Middle)

C/O SAVERS VALUE VILLAGE, INC.

11400 SE 6TH, SUITE 125

(Street)

BELLEVUE WA 98004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Savers Value Village, Inc. [ SVV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Services Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		M		12,000	A	$1.41	12,000	D
Common Stock	08/29/2025		S(1)		12,000	D	$11.98	0	D
Common Stock	09/02/2025		M		14,000	A	$1.41	14,000	D
Common Stock	09/02/2025		S(1)		14,000	D	$12.48	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Purchase)(2)	$1.41	08/29/2025		M			12,000	(3)	06/12/2029	Common Stock	12,000	$1.41	536,373(4)	D
Option (Right to Purchase)(2)	$1.41	09/02/2025		M			14,000	(3)	06/12/2029	Common Stock	14,000	$1.41	522,373(5)	D

Explanation of Responses:

1. The sale was made pursuant to a 10b5-1 Plan adopted by the reporting person on March 10, 2025.

2. Options previously granted under the Registrant's 2019 Management Incentive Plan. Each option represents the right to receive upon exercise one share of the Registrant's common stock subject to the applicable vesting and settlement conditions.

3. The June 12, 2019 stock option grant vested in substantially equal annual installments over five years starting March 28, 2020, and was fully vested on March 28, 2024.

4. Approximately 29% represents time-based options which vested in substantially equal annual installments over five years starting March 28, 2020 and approximately 71% represents performance-based options, of which 25% vested upon the initial public offering and the remainder will be eligible for vesting upon satisfaction of certain performance criteria including stock price performance.

5. Approximately 27% represents time-based options which vested in substantially equal annual installments over five years starting March 28, 2020 and approximately 73% represents performance-based options, of which 25% vested upon the initial public offering and the remainder will be eligible for vesting upon satisfaction of certain performance criteria including stock price performance.

Remarks:

	/s/ Richard Medway, attorney in fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What trades did Melinda L. Geisser report on Form 4 for SVV?

The Form 4 shows on 08/29/2025 a 12,000-share acquisition at $1.41 and a simultaneous 12,000-share sale at $11.98, and on 09/02/2025 a 14,000-share acquisition at $1.41 and a simultaneous 14,000-share sale at $12.48.

Were the sales made under a trading plan?

Yes. The filing states the sales were made pursuant to a 10b5-1 plan adopted March 10, 2025.

What option grants are referenced in the filing?

The filing references options granted on June 12, 2019 under the registrant's 2019 Management Incentive Plan, with time‑based and performance‑based vesting components.

How many derivative securities remain reported after the transactions?

Table II shows 536,373 and 522,373 underlying shares reported following the respective derivative transactions in the filing.

Who signed the Form 4 on behalf of the reporting person?

The Form 4 is signed /s/ Richard Medway, attorney in fact dated 09/03/2025.